All posts by medical

Neuroscience

Vanderbilt bonds with Nashville in the public school classroom – The Vanderbilt Hustler

Service organizations drive Vanderbilt students to become tutors and teachers in Nashvilles public schools.

Kleio JiangFebruary 7, 2020

Hundreds of volunteers in more than a dozen organizations on campus are dedicated to delivering interactive lessons to partner schools, in subjects ranging from English to Mathematics to Neuroscience. These organizations create their own syllabuses for one-on-one, interactive and even live broadcasting lessons that reach as far as schools in the most rural parts of Nashville. Much of this work, however, goes on behind the scenes.

The biggest service organization on campus, Vanderbilt Student Volunteers for Science (VSVS), has been gathering undergraduate, graduate and medical students since 1994. These volunteers not only collaborate with Metro Nashville public schools, but they also reach out to local science fairs, robotics teams and remote rural schoolsnot to mention Vanderbilt Childrens Hospital. VSVS has a specialized team that develops lessons specifically oriented around science, but public school students usually gain much more than that. VSVS encourages an interactive style of teaching, and the majority of questions posed by students are about college life.

These lessons give students not only a passion for science, but also the confidence to pursue higher education, VSVS Co-President Meghana Bhimreddy said.

But volunteering also benefits the volunteers themselves, many of whom now recognize the hardships of teachers nationwide in developing new teaching skills.

[To encourage participation among shy kids, one Vanderbilt student] brought a shiny pink karaoke mic to encourage class participation, Bhimreddy said.

Another service organization, Interaxon, is devoted to making neuroscience knowledge more accessible to its partner schools since 2011. Interaxon works with three Nashville Public schools and designs its programs based on feedback from the schools teachers to develop a syllabus that complements their students needs.

Just like most service events, the relationship between volunteers and students is a mutually beneficial one. Through the numerous questions about neuroscience that the students ask in childish yet insightful ways, volunteers are forced to come up with creative answers to satisfy their boundless curiosity.

This allows volunteers themselves to sharpen their own understanding of neuroscience knowledge, Interaxon School Director Puja Jagasia said.

In this way, volunteering at public schools is a unique experience that stands out from other service programs. Sometimes, volunteers even learn more from their students than the students learn from the volunteers.

Interaxon opened my lens on giving back to the community, Jagasia said. It is so far the most rewarding experience Ive had at Vanderbilt.

See the article here:
Vanderbilt bonds with Nashville in the public school classroom - The Vanderbilt Hustler

Neuroscience

Our brains map the world in a completely subjective fashion – The Big Smoke Australia

Sigmund Freud long theorised that our reality is influenced by our subconscious. With modern technology, neuroscientists have taken it further.

Modern advances have afforded neuroscientists a more comprehensive look inside the brains of humans as they interact with the world, and how our cranium translates into a cohesive map of the world around us. It has also shown us how subjective and malleable that map is, too.

Sigmund Freud, long before the inception of modern neuroscience, theorised that what we deem objective reality is altered by our subconscious.

Fast forward to now, with the invention of powerful imaging techniques, neuroscientists are now able to peer into the perceptions of people, whether it involves watching events in the environment, thinking about reality or making a decision between several possibilities.

Were able to go a lot deeper into understanding this massive machinery under the hood, says neuroscientist David Eagleman. One particularly interesting facet of our objective reality is the way in which we perceive time. People often report that time seems to slow down during a life-threatening situation, a novel event or even when playing sport.

Eagleman decided to put this to the test. By dropping people from a 150-foot tall tower and measuring their perception of time, he found that people dont necessarily see time moving slowly during an event like this. Rather, the brain creates supremely dense memories of the moment. Upon reflection, when one looks back on a shocking event like this, it appears time moved slower than usual at the moment because of the magnitude of information compressed into such a minuscule amount of time.

Neuroscience has drifted off a little bit from the directions that Freud was going in terms of the interpretations of whether your unconscious mind is sending you particular hidden signals and so on, said Eagleman. But the idea that theres this massive amount happening under the hood, that part was correct and so Freud really nailed that. And he lived before the blossoming of modern neuroscience, so he was able to do this just by outside observation and looking at how people acted.

Dr. Robert Lanza also explores the subjective nature of time in his book, Biocentrism. By penetrating to the bottom of matter, scientists have reduced the universe to its most basic logic, and time is simply not a feature of the external spatial world. Lanza believes that, to understand the fabric that binds the universe, we must take into account the role of the observer. By bringing to light how the electrical activity that occurs within the human brain somehow creates ones reality, Eagleman is carrying us one step closer to a biocentric view of reality.

Eaglemans new television series, The Brain, is almost like a tour of the universe that exists within us all. It wrestles simple yet unanswered questions aimed at helping viewers learn more about what it means to be human: What is reality? and Who is in control?

Nowadays, were able to peer noninvasively inside peoples heads as theyre doing tasks, as theyre thinking about things and making decisions, perceiving the world. Were able to go a lot deeper into understanding this massive machinery under the hood.

The show also provides a greater appreciation for the resiliency and adaptability of the brain. Just as time is altered from observer to observer, our brains dont stop developing. Were not fixed, said Eagleman. From cradle to grave, we are works in progress.

See more here:
Our brains map the world in a completely subjective fashion - The Big Smoke Australia

Neuroscience

Inadequate Myelination of Neurons Tied to Autism: Study – The Scientist

Insufficient myelination, likely caused by a lack of mature oligodendrocytes, is linked to autism spectrum disorder, according to a study in mice and postmortem human brains published yesterday (February 3) in Nature Neuroscience.

Myelin, the fatty substance that sheaths and insulates the axons of neurons, is responsible for aiding the quick delivery of signals throughout the brain. Too little myelin leaves the cells vulnerable to damage (as with multiple sclerosis), while too much can muddle the message. Oligodendrocytes (OL) are the cells that control myelination. Previous research has shown that myelin is typically thinner in those with autism spectrum disorder (ASD), while the current study explores the source of the problem.

While studying mouse brains for genetic mutations that cause Pitt-Hopkins syndrome, an autism-related genetic disorder, the team noticed irregular myelination and inconsistent expression of Tcf4, a gene that regulates OL activity.

Turning their attention to human cadavers, the researchers found deficiencies in myelin sheathing in brains from people with autism compared to controls, echoing what was found in the mice. A genetic analysis revealed that the homologous gene, TCF4, also contained varied mutations in regulatory regions. There was a noticeable lack of mature OL in the ASD brains when compared to the controls and an overabundance of immature cells, and myelination was not happening sufficiently.

This makes us think that the cells that are myelinating are doing it properly, its just that there are not a lot of them, coauthor Joseph Bohlen told Spectrum when his then-unpublished findings were presented at the Society for Neuroscience meeting in Chicago in October.

Future research will focus on the creation of brain organoids with irregular myelination and testing compounds that could target OL and increase myelin production. The authors hope is that if children with autism receive early identification, a treatment could mitigate some of their symptoms.

Lisa Winter is the social media editor forThe Scientist. Email her at lwinter@the-scientist.com or connect on Twitter @Lisa831.

Continued here:
Inadequate Myelination of Neurons Tied to Autism: Study - The Scientist

Neuroscience

Neuroscience Antibodies and Assays Market High-End Demand by Rising Industrial With Top Key Players Thermo Fisher, Abcam, Bio-Rad, Merck, Cell…

The Neuroscience Antibodies and Assays Market research Report is a valuable supply of perceptive information for business strategists. This Premium Tyres Market study provides comprehensive data which enhances the understanding, scope and application of this report.

The key market segments along with its subtypes are provided in the report. This report especially focuses on the dynamic view of the market, which can help to manage the outline of the industries. Several analysis tools and standard procedures help to demonstrate the role of different domains in market. The study estimates the factors that are boosting the development of Neuroscience Antibodies and Assays companies.

You can get the sample copy of this report now @https://www.reportsintellect.com/sample-request/220021

Key Companies Covered :Thermo Fisher, Abcam, Bio-Rad, Merck, Cell Signaling Technology, Genscript, Rockland Immunochemicals, BioLegend, Santa Cruz Biotechnology, Roche, Siemens

You get the detailed analysis of the current market scenario for Neuroscience Antibodies and Assays and a market forecast till 2024 with this report. The forecast is also supported with the elements affecting the market dynamics for the forecast period. This report also details the information related to geographic trends, competitive scenarios and opportunities in the Neuroscience Antibodies and Assays market. The report is also equipped with SWOT analysis and value chain for the companies which are profiled in this report.

Most Important Types :Consumables, Instruments

Most Important Application :Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers

Get Instant discount @https://www.reportsintellect.com/discount-request/220021

Global Neuroscience Antibodies and Assays Market Size, Status and Forecast 2019 2024

1 Market Overview

2 Manufacturers Profiles

3 Global Neuroscience Antibodies and Assays Sales, Revenue, Market Share and Competition by Manufacturer

4 Global Neuroscience Antibodies and Assays Market Analysis by Regions

5 North America Neuroscience Antibodies and Assays by Countries

6 Europe Neuroscience Antibodies and Assays by Countries

7 Asia-Pacific Neuroscience Antibodies and Assays by Countries

8 South America Neuroscience Antibodies and Assays by Countries

9 Middle East and Africa Neuroscience Antibodies and Assays by Countries

10 Global Neuroscience Antibodies and Assays Market Segment by Type

11 Global Neuroscience Antibodies and Assays Market Segment by Application

12 Neuroscience Antibodies and Assays Market Forecast

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendixes

Reasons for Buying this Report:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.

So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

sales@reportsintellect.com

PH +1-706-996-2486

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

Here is the original post:
Neuroscience Antibodies and Assays Market High-End Demand by Rising Industrial With Top Key Players Thermo Fisher, Abcam, Bio-Rad, Merck, Cell...

Neuroscience

Thermodynamic Theory of the Brain Aims To Understand Consciousness – Technology Networks

Consciousness is one of the brains most enigmatic mysteries. A new theory, inspired by thermodynamics, takes a high-level perspective of how neural networks in the brain transiently organize to give rise to memories, thought and consciousness.The key to awareness is the ebb and flow of energy: when neurons functionally tag together to support information processing, their activity patterns synchronize like ocean waves. This process is inherently guided by thermodynamic principles, which like an invisible hand promotes neural connections that favors conscious awareness. Disruptions in this process breaks down communication between neural networks, giving rise to neurological disorders such as epilepsy, autism or schizophrenia.

By using thermodynamic principles, such as energy gradients, dissipation and approach to equilibrium, we have a way to start comprehending, or characterizing, how mental things happen and how they sometimes deviate towards neuropathological states, said study author Dr. Jose L. Perez Velazquez affiliated with the Ronin Institute in Montclair, NJ.Energy States as a Guiding PrincipleScientists have long hypothesized that consciousness arises from the coordinated activity among neurons, widely spread across the brain. One framework, the Global Workspace Theory, posits that some brain regions integrate information over space and time across a large number of connected brain areas, resulting in data that is globally available for diverse processes such as memory, attention and language. Another hypothesis, the Integrated Information Theory, believes that consciousness is the result of heavily interconnected brain, the degree of which can be quantified.

Despite decades of work, these theories dont directly tackle the harder question: what are the principles guiding these connections, so that consciousness arises in the brain? As increasing effort focuses on communicating with locked-in patients and determining consciousness in intelligent machines, the pursuit of biological principles guiding brain organization becomes increasingly crucial.

The new work combines classical physics, especially some laws of thermodynamics, with modern recordings of neural activity, to paint a general framework of how changes in free energy the amount of energy available inside a system helps temporarily synchronize the activity in neural networks.

During conscious states, the brain has to actively integrate and segregate information from different senses and so consumes more energy than when unconscious. Using available neural recordings from human participants during wakefulness, sleep, coma and seizures each considered a brain macrostate the team found that entropy during consciousness was higher than that during unconscious states. As a concept, entropy can be interpreted and measured in many specific ways. Here, entropy is associated with the number of configurations of synchronized, or connected, brain networks.

Energy is dissipated as more neurons become connected, say Perez Velazquez and colleagues. Models using thermodynamic equations show that healthy and conscious states have a tendency toward greater dissipation.

However, it is not just about how much free energy is in the brain.

Each macrostate is composed of multiple configurable microstates. During conscious awareness, the brain has an optimal number of connected neural networks, and so many more microstates to support cognition. In contrast, during unconscious states like seizures, there are too many connected neural networks resulting in fewer microstates and so, lower entropy and higher free energy, causing the brain to malfunction.

To maintain healthy brain states then is not about the total amount of energy in the brain [] but rather in how the energy is organized, say the authors.A General Principle of Brain OrganizationTogether, viewing brain organization through the lens energy gradients and dissipation combines into a theory or tentatively, a principle that can separate healthy, conscious brain states from unconscious ones. The team thus believes that their approach can be used to further elucidate what happens when consciousness breaks, for example, in certain epileptic seizures.

Using the principle, the team offered an interpretation about how normal brain activity can transition into abnormal states. When neurons hyperactivate, this results in higher-than-normal synchrony that either lasts too long or reaches too wide regions of the brain. In other words, the brain settles on a state that is too stable. This idea agrees with a previous interpretation of consciousness, detailed in The Brain-Behavior Continuum The subtle transition between sanity and insanity.

As a result, the brain has lower entropy and so reduced ability to form variable brain activity patterns. That is, it has fewer microstates, resulting in fewer configurations of interacting neural networks, which deprives the brain of its usual ability to quickly and flexibly adapt to the outside world. In some cases, consciousness also crumbles.

The team has now laid out experiments to test the theory.ReferencePerez Velazquez et al. (2020) On a Simple General Principle of Brain Organization. Frontiers in Neuroscience. DOI: https://doi.org/10.3389/fnins.2019.01106

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See original here:
Thermodynamic Theory of the Brain Aims To Understand Consciousness - Technology Networks

Neuroscience

Malvern Festival of Ideas announces guest speaker Professor Colin Blakemore – Malvern Gazette

MALVERNS popular festival of ideas is returning once again with a new guest speaker once called 'one of the most powerful scientists in the UK'.

Colin Blakemore, professor of neuroscience and philosophy at the School of Advanced Study at the University of London and emeritus professor of neuroscience at the University of Oxford is the opening speaker at this years festival.

Professor Blakemore is the former chief executive of the British Medical Research Council as well as having hundreds of papers published in research journals.

He has been president of the British Neuroscience Association, the Physiological Society, the British Association for the Advancement of Science (now the British Science Association) and the Society of Biology.

The Observer newspaper once referred to him as One of the most powerful scientists in the UK. In parallel with his academic career, he has also has championed the communication of science and engagement with the public.

He has presented the BBC Reith Lectures and the Royal Institution Christmas Lectures.

In addition, he has written and presented many other programmes about science and written or edited several popular science books. He has also been honorary president of the Association of British Science Writers.

READ MORE: Vets closes due to major water leak

The theme of this years festival, is A Brave New World? and explores what can be done to look positively at the future as well as to what extent can ideas around social policy, economics, medicine, science, politics, psychology, arts, foreign policy and faith lead to a better world.

Speakers include the Labour peer professor baroness Ruth Lister, Dr Irene Guijt, head of research and publishing at Oxfam, Anthony Painter, leader of the research and impact team at the RSA, author and economics commentator Grace Blakeley, and philosopher Dr Julian Baggini. There will be a session on artificial intelligence and its impact on society with Dr Subramanian Ramamoorthy of Edinburgh University and Ivan Bartoletti. The weekend concludes with Peter Tatchell speaking on the future of LGBT+ rights.

All these talks take place at the Chase School and there is a family day at Malvern Cube on Saturday, March 7 with story teller and author Bernadette Russell.

For more information go to malvernfestivalofideas.org.uk/

View original post here:
Malvern Festival of Ideas announces guest speaker Professor Colin Blakemore - Malvern Gazette

Neuroscience

Researchers reveal new activity above the surface in brain-cell receptors – News-Medical.net

Like buoys bobbing on the ocean, many receptors float on the surface of a cell's membrane with a part sticking above the water and another underwater, inside the cell's cytoplasm. But for cells to function, these receptors must be docked at specific regions of the cell. Most research has focused on the 'underwater' portions. That's where the cell's molecular machines swarm and interact with a receptor's underwater tails, with those interactions then fueling signals that dive deep into the nucleus, changing the cell's course.

New work by a team of Thomas Jefferson University researchers reveals new activity above the surface, in brain-cell receptors that govern learning and chronic pain. In the study, the authors show that the 'above water' portion of proteins can help dock the proteins at synapses, where neurons mediate flow of information throughout the brain. This discovery opens the possibility of using this docking site as a target to develop treatments for chronic pain and other diseases more effectively. The study was published January 29th in Nature Communications.

"The extracellular spaces - the parts 'above the water' - have been largely overlooked," says senior author Matthew Dalva, PhD, professor and vice chair of the Department of Neuroscience and director of the Jefferson Synaptic Biology Center in the Vickie & Jack Institute for Neuroscience - Jefferson Health. Dr. Dalva and his team looked at the NMDAR receptor on brain cells and pinpointed the spot where this receptor interacts with a neighbor to initiate signaling. "When trying to develop new therapy, finding the bullseye is half the problem," says Dr. Dalva.

Finding a key interaction that sits above the cell's surface, could make it more accessible to therapeutics.

The kinds of receptor interactions we're talking about are different than when a receptor binds to its ligand outside of the cell, which is well documented. Here we're describing the kinds of biochemical exchanges - kinase phosphorylation fueled by free-floating ATP - that we thought, until recently, were exclusive to the inside of cells."

Dr. Matthew Dalva, senior author

The researchers focused on the synaptic protein called NMDA-type glutamate receptors (NMDARs), which help regulate the strength of synaptic connections between neurons. It's important that the synapse connects strongly, but not too strongly, in order to prevent creating an overly excitable connection.

A key mechanism controlling synaptic strength is the increase in NMDAR function due to direct molecular interaction with another synaptic protein called the EphB receptor tyrosine kinase. Dr. Dalva and colleagues had previously shown that the phosphorylation of EphB on the "outside" or extracellular portion of the molecule can lead to a direct interaction with NMDARs. And that chemical exchange causes the receptors to cluster and drive neuronal plasticity and chronic pain (PlosBiology 2017). Their new work identifies a specific region of the NMDAR or bullseye, necessary for these proteins to interact.

This specific bullseye could have important medical implications, as disruption of the EphB-NMDAR interaction has been associated with Alzheimer's, and in chronic pain can be due to too much of this interaction. As a trans-synaptic organizer and NMDAR binding protein, the EphB receptor is a key regulator of these events.

However, despite discovery of this interaction over a decade ago, the exact spot where NMDAR interacts with EphB has been a mystery. Here, the researchers demonstrate that specific amino acids in the hinge region of the NDMAR are required to interact with EphB2. Importantly, the amino acids in the hinge region are required for proper NDMAR mobility and stabilization at the synapse.

"There is growing evidence that extracellular interactions may play key regulatory roles in diseases ranging from pain to cancer and even malaria," says Dr. Dalva. "As we begin to define what these exchanges look like, we'll be able to study them, understand their contribution to disease and potentially use them to find better medical interventions."

Source:

Journal reference:

Washburn, H.R., et al. (2020) Positive surface charge of GluN1 N-terminus mediates the direct interaction with EphB2 and NMDAR mobility. Nature Communications. doi.org/10.1038/s41467-020-14345-6.

Follow this link:
Researchers reveal new activity above the surface in brain-cell receptors - News-Medical.net

Neuroscience

BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms – GlobeNewswire

NEW HAVEN, Conn., Feb. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that its Investigational New Drug (IND) application for BXCL501, the Companys proprietary sublingual thin-film formulation of dexmedetomidine (Dex), has received clearance from the U.S. Food and Drug Administration (FDA) for the treatment of opioid withdrawal symptoms.

The FDA clearance of our IND application for opioid withdrawal, a fourth indication, is an important step in our plans to build a neuroscience franchise around the multiple therapeutic opportunities with BXCL501, commented Vimal Mehta, Chief Executive Officer of BTI. Opioid overdose is reported as the number one cause of death for those under 50 years old in the U.S., and the distressing and challenging symptoms that come with opioid withdrawal are a primary reason for relapse. There is an urgent need for better treatment options to help manage the debilitating withdrawal symptoms and aid this underserved population from continued opioid abuse. BXCL501, our investigational non-opioid therapy, may offer key advantages to treating symptoms due to its intrinsic potency and favorable delivery method. We believe this study will build on the encouraging results we observed in our intravenous (IV) Dex trial, which appeared effective in reducing opioid withdrawal symptoms.

Opioid withdrawal is an emotional and physiological medical condition that may be driven by the excessive drive of noradrenergic neurons that originate from the locus coeruleus in the brainstem. BXCL501 selectively activates alpha-2a adrenergic receptors, which decreases excessive neuronal firing, alleviating the physiological symptoms of opioid withdrawal.

The RELEASE trial is a multicenter, randomized, double-blind, placebo-controlled, ascending-dose Phase 1b/2 study designed to evaluate the safety, pharmacokinetics, tolerability and efficacy of BXCL501 in patients experiencing symptoms of opioid withdrawal. This study will enroll subjects with opioid use disorder who are physically dependent on opioids. Patients will be randomized into multiple dose cohorts of BXCL501, or matching placebo, administered twice daily for five days. The study will assess opioid withdrawal symptoms using both the Clinical Opiate Withdrawal Scale and Short Opiate Withdrawal Scale of Gossop over a 10-day period.

About BXCL501BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in multiple clinical studies across multiple neuropsychiatric indications. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of agitation.

A Phase 1b safety and efficacy study of BXCL501 yielded positive dose-response data. BXCL501 is being evaluated in the SERENITY program, consisting of two Phase 3 studies for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). BXCL501 is also being evaluated in a Phase 1b/2 trial for the treatment of agitation associated with dementia, and the Company is preparing to initiate the Phase 1b/2 RELEASE trial of BXCL501 for the treatment of opioid withdrawal symptoms.

About Opioid Drug Withdrawal:

According to the Centers for Disease Control and Prevention (CDC), the misuse of and addiction to opioids is a serious national crisis and is the leading cause of death in the U.S. for those under 50 years old. Between 1999-2017, almost 400,000 people died from an overdose involving an opioid, with greater than 47,000 deaths occurring in 2017 alone. The CDC estimates the total "economic burden" of prescription opioid misuse alone in the U.S. is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment and criminal justice involvement. Opioid withdrawal is a condition characterized by symptoms such as anxiety, agitation, sleep problems, muscle aches, runny nose, sweating, nausea, vomiting, diarrhea and drug craving that occur after stopping or reducing the use of opioids in anyone with physical dependence on opioids.

About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer, pancreatic cancer and advanced solid cancers in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com/.

Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the effects of BXCL501 treatment on opioid withdrawal symptoms and the timing of clinical development initiatives and trials for BXCL501. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; its ability to commercialize its product candidates; and the other important factors discussed under the caption Risk Factors in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SECs website at http://www.sec.gov and on the Companys website at http://www.bioxceltherapeutics.com.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTIs views as of any date subsequent to the date of this press release.

BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations:John Grazianojgraziano@troutgroup.com1.646.378.2942

Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967

Source: BioXcel Therapeutics, Inc.

View original post here:
BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms - GlobeNewswire

Immunology

Quality Medical Management Services USA, LLC Signs Lease for Brand New, Expanded State-of-the-Art Space at Current 333 East Shore Rd Manhasset…

The new Manhasset office will now feature approximately 7,700 square feet of leading-edge technology and facilities.

Tarrytown, NY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Quality Medical Management Services USA, LLC, an affiliate of ENT and Allergy Associates, LLP, today announced that it has doubled down on its pledge to provide superior ENT, Allergy and Audiology healthcare services to the patients of Nassau County by signing a 10 year lease with East Shore Realty, LLC for a brand new, expansive clinical office at its current clinical office location at 333 East Shore Rd, Manhasset, NY, 11030.

This expansion allows ENTA physicians and other medical professionals to serve their patients needs with the increased benefit of 12 ENT exam rooms, 4 Allergy rooms, 3 audiology booths, a complete hearing aid dispensary, a full complement of allergy exam rooms for on-site testing and injections, and many other advantages. The Manhasset office will now feature approximately 7,700 square feet of leading-edge technology and facilities.

The expansion and renovations will be spearheaded by Nicole Monti-Spadaccini, Senior Vice President and Chief Operating Officer of QMMS USA. Ms. Monti currently oversees and directs the entire day to day operations for ENT and Allergy Associates, LLP.

This newly expanded and modernized location will complement the Practices other current Nassau County offices, in Garden City (990 Stewart Avenue, 6th floor, Suite 610, Garden City, NY, 11530) and Lake Success (3003 New Hyde Park Road, Suite 409, Lake Success, NY, 11042).

Philip Perlman, M.D., the senior ENTA partner in this office commented, Manhasset is an exciting place to live and work. Our neighborhood offers a dynamic environment that lends itself to young and old alike, singles and families wanting to take full advantage of the area. Our newly expanded office is now geared for further population growth and our patients deserve no less.

I have been practicing medicine in Nassau County for many years, added ENTA physician partner Mike Ditkoff, M.D. and I can tell you that we are extremely excited about what this new lease and facility upgrade will mean for patients in our communities.

Luke Donatelli, M.D, ENT physician in Manhasset commented, This expansion will offer extra comfort, extra convenience and truly state-of-the-art facilities. It further enhances our ability to provide what we already offer, which is the finest ear, nose, throat, allergy and audiology care possible. We are extremely pleased with this new lease.

Robert Glazer, EVP Chief Executive Officer of QMMS USA We are constantly looking for ways to improve the patient experience at our clinical locations. At our Manhasset office, we had the opportunity to upgrade and enhance without needing to move.Our expanded space provides additional exam rooms and procedure rooms as we look to recruit more high-quality otolaryngologists to this location. This is truly the best of all worlds. He continued With this expansion we are adding full time allergy, asthma and immunology services with the addition of Dr. Irum Noor to our clinical team. Dr. Noor will be supported by a team of well-educated and experienced nurses. In addition, we are subsequently expanding our audiology services, which combine the medical expertise of our ENT physicians and the diagnostic and rehabilitative skills of our licensed Doctors of Audiology to provide the most comprehensive care possible.

This expanded and improved facility is yet another example of ENTAs singular focus on both our patients healthcare, and the quality of their doctor visit experience, noted Robert Green, M.D., President of ENTA, Among other things, this new space means more comfort for everyone, and thats very important.

To learn more about ENTA, find a local office or book an appointment, download the ENT and Allergy Associates mobile app, visit http://www.entandallergy.com or call 1-855-ENTA-DOC.

About ENT and Allergy Associates LLP

ENT and Allergy Associates LLP (ENTA) has more than 220 physicians practicing in 46 office locations in Westchester, Putnam, Orange, Dutchess, Rockland, Nassau and Suffolk counties, as well as New York City and northern/central New Jersey. The practice sees over 90,000 patients per month. Each ENTA clinical location provides access to a full complement of services, including General Adult and Pediatric ENT and Allergy, Voice and Swallowing, Advanced Sinus and Skull Base Surgery, Facial Plastics and Reconstructive Surgery, Disorders of the Inner Ear and Dizziness, Asthma, Clinical Immunology, Diagnostic Audiology, Hearing Aid dispensing, Sleep and CT Services. ENTA has clinical alliances with Mount Sinai Hospital, Montefiore Medical Center, Northwell Health, and a partnership with the American Cancer Society.

Story continues

To learn more about QMMS USA, LLC, visit http://www.qmmsusa.com

About QMMS USA, LLC: Backed by over 20 years of experience, Quality Medical Management Services USA (QMMS USA) offers healthcare consultancy services in the area of medical staff operations, practice management, ancillary service revenue enhancement, compliance, records management, and business applications. QMMS USA provides a seasoned team to offer leading edge healthcare business management. QMMS USA implements best practices throughout to ensure success.

Jason CampbellENT and Allergy Associates, LLP9149842531jcampbell@entandallergy.com

View post:
Quality Medical Management Services USA, LLC Signs Lease for Brand New, Expanded State-of-the-Art Space at Current 333 East Shore Rd Manhasset...

Immunology

UHS board considers thesis reports – The News International

UHS board considers thesis reports

LAHORE:The 154th meeting of Advanced Studies and Research Board of the University of Health Sciences (UHS) was held here on Thursday with Gujranwala Medical College, Gujranwala, Principal Prof Dr Maroof Aziz Khan in the chair.

The board considered the thesis reports of Dr Mahwish Farzana, MD (radiology), Dr Ayman Nasieb, MS (cardiothoracic Surgery), Dr Matiur Rahman, MS (cardiac surgery) and Dr Salik Nazeer Qaisrani, MS (urology). The synopses of the following students were also considered for registration in various postgraduate courses: Dr Ghanwa Saeed, MPhil (immunology), Mahwish Asif, MPhil (microbiology), Faiqa Munir, MPhil (human genetics and molecular biology), Dr Syed Muhammad Saad Gardezi, MPhil (pharmacology), Dr Hafsa Faiz, MPhil (pharmacology), Dr Hammad Hassan, MPhil (science of dental materials), D. Huda Mehmood, MDS (prosthodontics), Dr Zoha Rahim, MD (gastroenterology), Dr Muhammad Asad Munir, MS (orthopaedics), Dr Mehreen Gul, MS (Obst. & Gynae.) and Dr Umair Rahim Khan, MS (plastic surgery).

See the article here:
UHS board considers thesis reports - The News International